Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstaZeneca shares with a ...

AstraZeneca's new drug, baxdrostat, has successfully lowered blood pressure in a late-stage trial for treatment-resistant ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

The UK's FTSE 100 index neared its peak with a boost from AstraZeneca's successful drug trial, amid scrutiny on U.S. tariffs ...

AstraZeneca’s (LON: AZN) experimental drug baxdrostat lowered blood pressure in patients with hard to treat hypertension, ...

AstraZeneca has announced that its Baxdrostat hypertension treatment met the primary and secondary endpoints in a Phase III ...

Shares of AstraZeneca PLC AZN shed 1.66% to £104.50 Friday, on what proved to be an all-around dismal trading session for the ...

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...

AstraZeneca's experimental drug baxdrostat has been successful in lowering high blood pressure in a late-stage study of ...